Search for new therapeutic options for the uncommon pathogen Mycobacterium chimaera: an open drug discovery approach


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/103625/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
Searching for new therapeutic options for the uncommon pathogen Mycobacterium chimaera: an open drug discovery approach

Daire Cantillon, Aaron Goff, Stuart Taylor, Emad Salehi, Katy Fidler, Simon Stoneham, Simon J Waddell

Summary

Background Mycobacterium chimaera is a slowly growing non-tuberculous mycobacterium associated with outbreaks of fatal infections in patients after cardiac surgery, and it is increasingly being detected in patients with chronic lung conditions. M chimaera can cause disseminated disease, osteomyelitis, and chronic skin or soft-tissue infections. We aimed to find new inhibitory compounds and drug repurposing opportunities for M chimaera, as current therapeutic options often result in poor outcomes.

Methods In an open drug discovery approach, we screened the Medicines for Malaria Venture (MMV) Pathogen Box to assess the in-vitro antimicrobial drug susceptibility of M chimaera compared with the antimicrobial drug susceptibility of the slowly growing, major human pathogen Mycobacterium tuberculosis, and the rapidly growing Mycobacterium abscessus reference strains. Compounds identified from an initial resazurin microtitre cell viability assay screen were further characterised by determining the minimum inhibitory concentration (MIC) of MMV Pathogen Box compounds against M chimaera; and the MICs of a panel of 20 drugs commonly used to treat mycobacterial infections against M tuberculosis, M abscessus, and M chimaera. We also assessed the time-kill kinetics of doxycycline, clarithromycin, ethambutol, and rifabutin against M chimaera.

Findings M chimaera was inhibited by 21 (5%) of 400 compounds in the Pathogen Box. Ten compounds were active against all three mycobacteria. MMV675968, with activity against slowly growing mycobacteria that probably targets folate metabolism, had a mean MIC of 2.22 µM (0.80 µg/mL) against M chimaera. Antimicrobial susceptibility testing showed that oxazolidinones such as linezolid (mean MIC 3.13 µg/mL) were active against M chimaera and that bedaquiline was the most potent compound (mean MIC 0.02 µg/mL). Doxycycline, a broad-spectrum antimicrobial drug with excellent tissue penetration properties, also inhibited M chimaera with a mean MIC of 6.25 µg/mL.

Interpretation Molecular diagnostics present an opportunity for more effective, targeted drug therapies—treating bacterial infections at the species level. Using an open drug discovery platform, we identified compounds that inhibit the newly recognised pathogen M chimaera. The existing evidence base is poor and the option for expensive drug discovery is improbable; therefore, we have also found options for drug repurposing. Future in-vivo efficacy studies will reveal whether these findings result in new, targeted treatment regimens for M chimaera.

Funding Wellcome Trust, National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), and the University of Sussex Junior Research Associate scheme.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

Mycobacterium intracellulare subspecies chimaera (M chimaera) is a slowly growing non-tuberculous mycobacterium of the Mycobacterium avium complex. It was first recognised in 2004, and interest in it developed quickly after numerous outbreaks of prosthetic valve endocarditis and disseminated disease in patients who had undergone cardiopulmonary bypass surgery. Whole-genome sequencing of isolates suggested a single common source, which was traced to heater–cooler units used during cardiac surgery. M chimaera disease onset is typically more than 1 year after surgery, it is resistant to antimicrobial drug therapy, and it results in high mortality. Cardiac disease is the greatest cause of death globally and it is rising rapidly in low-income and middle-income countries; as the incidence of cardiac surgery increases, so too will the risk of nosocomial infection.

M chimaera disease after cardiac surgery can present with endocarditis, chronic sternal wound infection, or disseminated infection. In addition, M chimaera is increasingly being detected in patients with chronic lung disease, such as cystic fibrosis or chronic obstructive pulmonary disease, and causes disseminated disease, osteomyelitis, and chronic skin or soft-tissue infections. The number of M chimaera cases is probably under-reported, and the misdiagnoses of infections result in delayed and inappropriate treatment. Improved molecular diagnostics will result in more frequent
identification of uncommon mycobacterial infections, which offers opportunities to treat patients using specialised, effective drug regimens tailored to each bacterium.

The American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America joint clinical practice guideline recommends the treatment of *M avium* complex pulmonary disease on the basis of disease severity, and it does not distinguish treatment by subgroup speciation. In severe disease, treatment involves daily rifampicin, ethambutol, azithromycin, and occasionally addition of intravenous or nebulised amikacin. Therapy should be continued for up to one year after conversion to culture negative. In one UK study, 15 (60%) of 25 patients with postoperative *M chimaera* died; ten of those who died received treatment for *M chimaera*. The high mortality rate despite 12 months of antimicrobial therapy highlights the challenge of treating *M chimaera* in at-risk patients with multiple comorbidities.

Antimicrobial drug susceptibility testing of subspecialised *M avium* complex clinical isolates revealed broadly similar drug susceptibilities, with some minor differences between isolates. Schulthess and colleagues also reported comparable drug susceptibilities between *M chimaera* and *M avium*. However, the microbiological and clinical diversity of *M avium* complex infections suggests that effective targeted therapeutic options might exist.

Using an open drug discovery approach, this study aimed to address the challenge of delivering new treatment options for *M chimaera*, in which the existing evidence base is poor and the rational for expansive drug discovery research is unjustified.

**Methods**

**Study design and cultures**

We adopted an open drug discovery approach for this study, which was done between Aug, 8, 2018, and March, 1, 2020, in the Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, UK.

*M chimaera* reference strain NCTC13781, *Mycobacterium abscessus* reference strain ATCC19977, and *Mycobacterium tuberculosis* reference strain H37Rv (from the National Collection of Type Cultures, Public Health England) were
cultured in Middlebrook 7H9 broth (Sigma Aldrich, St Louis, MO, USA) supplemented with albumin dextrose catalase (ADC; 10% volume per volume [v/v]) and Tween 80 (0.05% v/v; Sigma Aldrich, St Louis, MO, USA) at 37°C. Optical density was measured using a spectrophotometer at absorbance 600 nm. Colony forming units (CFUs) were determined by serially diluting cultures onto Middlebrook 7H10 agar (Sigma Aldrich, St Louis, MO, USA) supplemented with 0.5% glycerol and oleic acid albumin dextrose catalase (OADC; 10% v/v) and incubated at 37°C for 4 weeks for *M tuberculosis*, 3 weeks for *M chimaera*, and 3 days for *M abscessus*. Laboratory work with *M chimaera* and *M abscessus* were conducted in biosafety level-2 laboratories; work with *M tuberculosis* was conducted in a biosafety level-3 laboratory. This study did not require ethics permissions or Institutional Review Board approval.

**Procedures**

**Assay validation for *M chimaera***

We validated the resazurin microtitre cell viability assay (REMA) as a screening method, REMA (CellTiter-Blue, Promega, Madison, WI, USA) was used to determine the antimicrobial activities of the drugs. Log phase *M chimaera* cultures were diluted to 1×10⁵–5×10⁹ CFU/mL, inoculated into a series of drug-free wells containing 2% v/v dimethyl sulfoxide (Sigma Aldrich, St Louis, MO, USA) and into wells containing 2.5 µg/mL rifampicin (50 times the minimum inhibitory concentration [MIC]; Sigma Aldrich, St Louis, MO, USA), and incubated at 37°C for 7 days. A 2% dimethyl sulfoxide concentration was selected to match the final dimethyl sulfoxide concentration of the Pathogen Box screen. To determine antimicrobial activity, CellTiter-Blue was added at a final concentration of 10% v/v and incubated for 16 h. Fluorescence was measured at excitation 580–640 nm and emission 520 nm, using a Glomax Discover plate reader (Promega, Madison, WI, USA). Fluorescence data were corrected for background using media-dimethyl sulfoxide bacteria-free controls. Experiments were repeated a minimum of three times and the datapoints were pooled.

**Pathogen Box whole cell screen for antimycobacterial activity***

We screened the Medicines for Malaria Venture (MMV) Pathogen Box to assess the in-vitro antimicrobial drug susceptibility of *M chimaera* compared with the antimicrobial drug susceptibility of slowly growing, major human pathogen *M tuberculosis*, and the rapidly growing *M abscessus*. The Pathogen Box contained 400 drug-like compounds active against various neglected diseases, including 21 reference compounds with known antimicrobial activity; the concentration of the compounds provided was 10 mM in 100% dimethyl sulfoxide. Log phase cultures of *M chimaera*, *M abscessus*, and *M tuberculosis* were diluted to 1×10³–5×10⁹ CFU/mL and added to 96-well plates containing Pathogen Box compounds at a final concentration of 20 µM (2% v/v dimethyl sulfoxide). Drug-free controls were inoculated alongside drug controls of 5 µg/mL rifampicin (>1000 times the MIC against *M tuberculosis*; 100 times the MIC against *M chimaera*) or 3.9 µg/mL MIC clarithromycin (3 times the MIC against *M abscessus*). Plates were incubated at 37°C for 3 days for *M abscessus* and 7 days for *M chimaera* and *M tuberculosis*. Antimicrobial activity was assessed using REMA. Background fluorescence was corrected by adjusting measurements to media-dimethyl sulfoxide bacteria-free controls. Hits were classed as compounds that inhibited bacterial growth by 70% or more compared with drug-free controls (appendix p 2).

**Determination of MICs**

We measured the MICs of MMV compounds that had hits against *M chimaera* and to repurpose commonly used antimycobacterial drugs for *M chimaera* we measured the MIC of 20 drugs used in first-line or second-line tuberculosis treatment, or that treat non-tuberculous mycobacteria. All drugs were prepared as 10 mg/mL stock solutions in sterile dimethyl sulfoxide, except for rifampicin and rifabutin, which were prepared with 90% weight per volume methanol, and aminoglycosides, which were prepared in sterile water. Single use drug aliquots were stored at −20°C. MICs were determined using a microbroth dilution method as recommended by the Clinical and Laboratory Standards Institute (CLSI) for non-tuberculous mycobacteria, but with modifications (appendix p 3). Middlebrook 7H9 broth (0.05% Tween 80, 10% ADC) was used as the culture media to enable comparison between the three mycobacteria. Two-fold dilutions of the 20 antimicrobial compounds or three-fold dilutions of the MMV compounds were prepared in 96-well microtitre plates and inoculated with mycobacteria to a final concentration of 1×10³–5×10⁵ CFU/mL. The plates were incubated at 37°C for 3 days for *M abscessus* and 7 days for *M chimaera* and *M tuberculosis*.

MIC values were estimated by REMA after 16 h incubation with CellTiter-Blue. Fluorescence data were corrected for background using media-only controls. The MIC was defined as the minimum concentration of compound required to inhibit bacterial growth by 90% or more, except for ethambutol and ethionamide for which the MIC was calculated as the lowest concentration of the drug to consistently inhibit growth because 90% inhibition could not be obtained. Positive controls were drug-free wells that were included to assay uninhibited mycobacterial growth. Negative controls were bacteria-free, drug-free wells that were included to define background fluorescence and assess sterility of the assay. Experiments were repeated a minimum of three times, with triplicate datapoints per experiment. We calculated the mean MIC from a minimum of nine datapoints.
M. chimaera time-kill assay

Time-kill assays of doxycycline, clarithromycin, ethambutol, and rifabutin were conducted for M. chimaera. Log phase Middlebrook 7H9 broth cultures, corresponding to 10^8 CFU/mL in 20 mL volumes, were treated with two times or ten times the drug MIC or dimethyl sulfoxide carrier control and incubated at 37°C with shaking at 180 revolutions per min. Optical density and CFU counts were determined at 0, 4, 7, 10, and 14 days.

Statistical analysis

REMA was validated as a screening method by calculating the estimated Z factor, where the degree of separation
between positive and negative controls determines the reliability of the assay. A value between 0.5 and 1.0 indicates that an assay is statistically reliable enough to discriminate between positive and negative control wells; the closer to 1.0, the more robust the assay. The estimated Z factor for the Pathogen Box REMA screen was determined using the formula:

\[
Z\text{factor} = 1 - \frac{3(\sigma_p + \sigma_n)}{|\mu_p - \mu_n|}
\]

In this formula, \( \sigma_p \) is the standard deviation of the positive controls; \( \sigma_n \) is the standard deviation of the negative controls; \( \mu_p \) and \( \mu_n \) are the means of the positive and negative controls, respectively. The \( \text{M chimaera} \) REMA assay estimated Z factor comparing drug-free bacilli with rifampicin-treated bacilli was 0.87, demonstrating that this screening method was statistically robust and appropriate for assessing antimicrobial drug activity. Error bars were assigned to MIC plots by applying SD of pooled technical replicates from three independent experiments in GraphPad Prism (version 9).

**Role of the funding source**

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

**Results**

Of the 400 Pathogen Box compounds, 21 compounds showed activity in the REMA screen against \( \text{M chimaera} \), 57 compounds were active against \( \text{M tuberculosis} \), and 14 compounds were active against \( \text{M abscessus} \) (figure 1; appendix pp 7–16). Only ten compounds in the Pathogen Box were active against all three mycobacteria. Of the 400 Pathogen Box compounds, 21 compounds were previously defined as active against mycobacteria (ie, established antimicrobial drugs). These were rifampicin, part of the first-line treatment for drug-sensitive tuberculosis and \( \text{M avium} \) complex; clofazimine and linezolid used in non-tuberculous mycobacterial pulmonary disease; bedaquiline and ofloxacin options for the treatment of multidrug-resistant tuberculosis; and dosycycline, a broad-spectrum tetracycline antimicrobial drug that was a potent inhibitor of \( \text{M chimaera} \) inhibiting growth by approximately 90%. 11 (73%) of 15 MMV hits were previously defined as active against mycobacteria in a screen of \( \text{M tuberculosis} \): MMV688327, MMV688508, MMV676395, MMV688845, MMV688756, MMV687703, MMV688844, MMV687146, MMV461553, MMV153413, and MMV687729. The four remaining compounds active against \( \text{M chimaera} \) were not classed as anti-tuberculosis drugs and further compound was requested from MMV to determine MICs (MMV675968, MMV688271, MMV688179, and MMV688271); two were characterised as anti-kinetoplastid, one as anti-malarial, and one as anti-cryptosporidiosis. MICs confirmed dose-responsive activity of these compounds against \( \text{M chimaera} \) (figure 2). The mean MICs were 2.22 μM (0.80 μg/mL) for MMV675968, 20 μM (9.52 μg/mL) for isomers MMV688179 and MMV688271, and 60 μM (32.76 μg/mL) for MMV022478. All four compounds display favourable druggable characteristics (appendix pp 17–18), thus contributing to the portfolio of antimicrobial activities for these compounds.

Since the primary screen revealed that the majority of \( \text{M chimaera} \) hits were also active against \( \text{M tuberculosis} \), we measured MICs in \( \text{M chimaera} \), and \( \text{M abscessus} \),
Articles

<table>
<thead>
<tr>
<th>Aminoglycoside</th>
<th>Mean MIC against M chimaera, µg/mL</th>
<th>Mean MIC against M tuberculosis, µg/mL</th>
<th>Mean MIC against M abscessus, µg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>5.210 (1.800)</td>
<td>0.195 (0)*</td>
<td>10.417 (3.610)</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>3.120 (0)</td>
<td>0.156 (0)*</td>
<td>12.500 (0)</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>0.780 (0)</td>
<td>0.200 (0)*</td>
<td>10.417 (3.610)</td>
</tr>
</tbody>
</table>

| Aminosalicylate             |                                    |                                       |                                     |
| Ammonium citrate            |                                    |                                       |                                     |
| Carbenem                    |                                    |                                       |                                     |
| Diaperidil                  |                                    |                                       |                                     |
| Ethylenediamine             |                                    |                                       |                                     |
| Ciprofloxacin               |                                    |                                       |                                     |
| Moxifloxacin                |                                    |                                       |                                     |
| Oxofloxacin                 |                                    |                                       |                                     |
| Hydrazide                   |                                    |                                       |                                     |
| Isoniazid                   |                                    |                                       |                                     |
| Macrolide                   |                                    |                                       |                                     |
| Azithromycin                |                                    |                                       |                                     |
| Clarithromycin              |                                    |                                       |                                     |
| Erythromycin                |                                    |                                       |                                     |
| Oxazolidine                 |                                    |                                       |                                     |
| Linezolid                   |                                    |                                       |                                     |
| Phinafine                   |                                    |                                       |                                     |
| Clofazimine                 |                                    |                                       |                                     |
| Rifamycin                   |                                    |                                       |                                     |
| Rifampicin                  |                                    |                                       |                                     |
| Rifinamid                  |                                    |                                       |                                     |
| Tetracycline                |                                    |                                       |                                     |
| Doxycycline                 |                                    |                                       |                                     |
| Thioamide                   |                                    |                                       |                                     |

| Ethambutol                  | 5.210 (1.800)                     | 0.195 (0)*                            | 10.417 (3.610)                      |
| Ethambutol                  | 3.120 (0)                         | 0.156 (0)*                            | 12.500 (0)                          |
| Tobramycin                  | 0.780 (0)                         | 0.200 (0)*                            | 10.417 (3.610)                      |

Data are mean (SD) unless indicated otherwise. There was no more than one dilution difference in MICs between biological replicates. MICs were determined using the microbroth dilution method from three independent biological replicates. The table is ordered by drug class. MIC=minimum inhibitory concentration. *The lowest MIC value for each biological replicate and SD.

Table: MICs of commonly prescribed antimycobacterial drugs against Mycobacterium chimaera, Mycobacterium tuberculosis, and Mycobacterium abscessus

and M tuberculosis for 20 first-line and second-line anti-tuberculosis drugs alongside drugs that have been prescribed to treat non-tuberculous mycobacteria (table). Isoniazid showed no activity against M chimaera or M abscessus (mean MICs >200 µg/mL), despite its use clinically for clarithromycin-resistant M chimaera infections.18 Ethambutol, a first-line agent for M chimaera, showed activity against M chimaera with a mean MIC of 6-25 µg/mL. However, this drug only inhibited growth by 70–80%, even at the highest concentration tested of 200 µg/mL. A similar result was observed for ethionamide, with M chimaera growth inhibited by 70–80% at concentrations of 25 µg/mL. Neither of these cell wall-targeting agents inhibited M abscessus (mean MICs >200 µg/mL). Rifampicin and rifabutin showed potent activity against M chimaera (mean MIC 0.05 µg/mL for both), with rifabutin more active than rifampicin in M abscessus. Bedaquiline was the most potent antimicrobial drug tested against M chimaera with a mean MIC of 0.02 µg/mL; it was also active against M abscessus with a mean MIC of 0.39 µg/mL. Linezolid, a component of regimens used to treat pulmonary M avium complex disease in cases for which resistance to first-line agents is identified, was effective against all three mycobacteria, with mean MICs of 3.13 µg/mL against M chimaera, 6-25 µg/mL against M abscessus, and 1-56 µg/mL against M tuberculosis. The next generation oxazolidinones, radezolid and sutezolid, also inhibited M chimaera. Clofazimine and aminosalicylic acid showed activity against M chimaera with a mean MIC of 0.20 µg/mL and 6-25 µg/mL, respectively.

Aminoglycosides are sometimes added to M chimaera drug regimens, and they are important second-line drugs for multidrug resistant tuberculosis. For M tuberculosis, the amikacin mean MIC was 0.195 µg/mL and the streptomycin mean MIC was 0.156 µg/mL. However, the concentrations required for non-tuberculous mycobacteria were higher with 27 times more amikacin (5-21 µg/mL) and 20 times more streptomycin (3-13 µg/mL) required for M chimaera, and 53 times more amikacin (10-42 µg/mL) and 80 times more streptomycin (12-5 µg/mL) required for M abscessus. Amikacin and tobramycin can be delivered as nebulised drugs, and the tobramycin mean MIC for M chimaera (0.78 µg/mL) was almost seven times lower than the mean MIC of amikacin (5-21 µg/mL). The fluoroquinolones ciprofloxacin, moxifloxacin, and ofloxacin...
were all active against *M chimaera*, with a ciprofloxacin mean MIC of 0·78, a moxifloxacin mean MIC of 0·20, and an ofloxacin mean MIC of 2·61 µg/mL. The macrolide clarithromycin is a first-line drug for *M chimaera*; and clarithromycin was the most potent macrolide with a mean MIC of 0·39 µg/mL, azithromycin had a mean MIC of 10·42 µg/mL, and erythromycin had a mean MIC of 8·33 µg/mL. Clarithromycin was also the most active macrolide against *M tuberculosis* (1·30 µg/mL mean MIC) and *M abscessus* (1·04 µg/mL mean MIC). The order of macrolide in-vitro efficacy was clarithromycin followed by erythromycin, and then azithromycin for all three mycobacteria. Imipenem, a carbapenem that is highly stable against many β lactamases, and has been used to treat *M chimaera*, had a mean MIC of 8·33 µg/mL.

Doxycycline, which has been used to treat *M abscessus*, was identified as a hit in our Pathogen Box screen. We determined a doxycycline mean MIC against *M chimaera* of 6·250 µg/mL, 3·125 µg/mL against *M tuberculosis*, and 50 µg/mL against *M abscessus* (figure 3). The slowly growing *M chimaera* and *M tuberculosis* were more sensitive to doxycycline, whereas the rapidly growing *M abscessus* was only inhibited by doxycycline at concentrations of 50 µg/mL or higher. Doxycycline has been widely reported to be bacteriostatic and we verified this by measuring time-kill kinetics alongside clarithromycin, ethambutol, and rifabutin (the first-line drugs for *M chimaera*). Doxycycline was bacteriostatic against *M chimaera* (figure 4A), and there was no regrowth of bacteria over time when treated with two times the doxycycline mean MIC (12·50 µg/mL) or ten times the doxycycline mean MIC (62·50 µg/mL). *M chimaera* regrowth after 14 days was observed when treated with two times the clarithromycin mean MIC (0·78 µg/mL), ten times the clarithromycin mean MIC (3·90 µg/mL), two times the rifabutin mean MIC (0·10 µg/mL), ten times the rifabutin mean MIC (6·25 µg/mL), and two times the ethambutol mean MIC (12·50 µg/mL; figure 4B–D).

**Discussion**

The development of molecular diagnostic tools that differentiate bacterial infections at the species level offers unprecedented opportunities to personalise more effective antimicrobial drug therapies to treat rare pathogens. To realise effective therapies, simple discovery pathways must signpost potential therapeutic combinations. We optimised a viability assay for *M chimaera* and screened the open drug discovery MMV Pathogen Box, comprising 400 drug-like compounds with antimicrobial activity, low cytotoxicity, and favourable drug kinetics against reference strains of three pathogenic mycobacteria (*M chimaera*, *M tuberculosis*, and *M abscessus*). This approach enabled a broad comparison of drug efficacy for *M chimaera* with the rapidly growing *M abscessus* and slowly growing *M tuberculosis*. Our findings also contribute to open-source drug discovery efforts for emerging bacterial threats and neglected tropical diseases. We determined the MICs for Pathogen Box hits alongside established antimicrobial drugs, identifying new antimycobacterial compound activities and drug repurposing options for *M chimaera*.

Of the 21 MMV Pathogen Box compounds that inhibited *M chimaera*, six were reference compounds with established antimicrobial activity, 11 were classed as anti-tuberculosis drugs, two as anti-kinetoplastid, one as antimalarial, and one as anti-cryptosporidiosis. We determined the MICs of four hits with novel antimycobacterial activity, MMV675968, a diaminoquinazoline, had a mean MIC of 2·22 µM (0·80 µg/mL) against *M chimaera*, and also inhibited *M tuberculosis*. It is classed as an anti-cryptosporidiosis compound that targets dihydrofolate reductase, a key enzyme in the mycobacterial cellular processes of folate metabolism and nucleotide synthesis. This enzyme is a target of the tuberculosis drug aminosalicylic acid, and it is the focus of continued drug discovery efforts. We established an aminosalicylic acid mean MIC of 6·25 µg/mL for *M chimaera*, highlighting the potential of exploiting folate metabolism for *M chimaera* drug development with new and existing chemical entities. MMV022478, with a mean MIC of 60 µM (32·76 µg/mL) against *M chimaera* and activity against *M tuberculosis* and *M abscessus*, is a pyrazolopyrimidine with in-vitro activity against the parasite *Trypanosoma brucei*. MMV022478 has...
been shown to inhibit protein kinase C which activates nicotinamide adenine dinucleotide phosphate oxidase in eukaryotic cells, thus inhibiting a range of cellular processes.\textsuperscript{20} MMV688179 and MMV688271 isomers, both with a mean MIC of 20 µM (9-52 µg/mL) against \textit{M. chimaera} and possessing activity against \textit{M. tuberculosis}, are bisarylguanidiniums that bind to the minor groove of adenine-thymine rich regions of DNA, and they possess activity against a wide range of trypanosomal parasite life stages.\textsuperscript{21} This class of compounds might also have affinity for mammalian DNA,\textsuperscript{20} although they showed low toxicity against human cell lines (appendix p 18).\textsuperscript{12} We identified ten antimicrobial compounds that inhibited all three mycobacterial pathogens screened (MMV688179, MMV022478, MMV688508, MMV68844, MMV68845, and the reference drugs levofloxacin, linezolid, rifampicin, bedaquiline, and duropezolid). MMV688508, MMV68844, and MMV68845 are already classified as anti-tuberculosis compounds, and MMV688179 and MMV022478 were newly identified to inhibit mycobacteria in this study. Activity against both rapidly growing and slowly growing mycobacteria suggest that these compounds have broad antimycobacterial activity worthy of further investigation.

The MMV Pathogen Box has been applied previously to drug discovery for \textit{M. tuberculosis}, \textit{M. abscessus}, and \textit{M. avium}.\textsuperscript{16,21} The correlation between drug screening studies for \textit{M. abscessus} was high, with 11 of 13 hits from Low and colleagues’ study\textsuperscript{21} identified in this study alongside three additional compounds (appendix p 4). However, a comparison of \textit{M. avium} with \textit{M. chimaera} drug screening studies revealed a lower number of overlapping effective compounds, with 17 of 33 \textit{M. avium} hits from Low and colleagues’ study found to inhibit \textit{M. chimaera} in this study (appendix p 5). The low overlap of hits between \textit{M. avium} and \textit{M. chimaera} (in comparison to the high similarity between \textit{M. abscessus} screens), suggests that \textit{M. chimaera} drug susceptibilities might not always match that of \textit{M. avium}. Indeed, 16 compounds were identified to have anti-\textit{M. avium} activity by Low and colleagues that did not inhibit \textit{M. chimaera} in this study.

To repurpose commonly used antimycobacterial drugs for \textit{M. chimaera}, we determined the MICs of tuberculosis and non-tuberculous mycobacteria antimicrobial drugs against \textit{M. chimaera}, \textit{M. tuberculosis}, and \textit{M. abscessus}. Bedaquiline, clofazimine, moxifloxacin, erythromycin, azithromycin, and clarithromycin had the lowest MIC values against \textit{M. chimaera} of the three mycobacteria. The oxazolidinones (linezolid, duropezolid, and sutezolid), which bind to the ribosome to prevent translation initiation, inhibited \textit{M. chimaera}, suggesting that these might be useful drugs. The oxazolidinones were also three of the top ten hits against \textit{M. avium} in the study by Low and colleagues.\textsuperscript{23} The most effective aminoglycoside against \textit{M. chimaera} was tobramycin, which can be administered intravenously or via a nebuliser, which suggests that tobramycin should be compared with amikacin for \textit{M. chimaera} pulmonary infections, the currently recommended aminoglycoside. However, unlike amikacin, no tobramycin breakpoints exist for \textit{M. avium} complex, and it is not known whether tobramycin MICs correspond to clinical efficacy.

Bedaquiline was the most potent antimicrobial drug tested against \textit{M. chimaera} (mean MIC 0·02 µg/mL). Bedaquiline is used safely and effectively to treat multidrug-resistant tuberculosis; its efficacy against slowly growing non-tuberculobus mycobacteria has been demonstrated in vitro, with bacteriostatic activity from 0·007 to 0·03 µg/mL and bactericidal activity from 1 to 2 µg/mL.\textsuperscript{21} A bedaquiline-clofazimine combination was shown to be synergistic and additive in vitro against \textit{M. chimaera}.\textsuperscript{21} Clinical studies of bedaquiline efficacy against non-tuberculobus mycobacteria are limited in number. In a cohort of ten patients with chronic \textit{M. avium} complex or \textit{M. abscessus} pulmonary disease, treatment with a regimen containing bedaquiline led to a moderate clinical response of 50% of patients reaching conversion to culture negative after six months of treatment.\textsuperscript{24} The cost and potential side-effects in patients with \textit{M. chimaera} and multiple comorbidities might also be a concern; however, bedaquiline might prove to be a useful therapeutic option for \textit{M. chimaera}. Doxycycline was demonstrated to have activity against \textit{M. chimaera}, with a mean MIC of 6·250 µg/mL. To date, no breakpoints have been set for this drug in \textit{M. chimaera}.\textsuperscript{3} Patient case studies have shown that \textit{M. chimaera} can spread into bone, limiting treatment options.\textsuperscript{1,3} Doxycycline is highly lipophilic, acting on intracellular bacteria, and it is rapidly distributed in bone and muscle where disseminated \textit{M. chimaera} infections can reside. Importantly, doxycycline has an excellent safety profile for long-term use, and it has the pharmacodynamic and pharmacokinetic properties of a potentially effective antimycobacterial agent, including crossing the blood–brain barrier. Doxycycline is recommended for the long-term treatment of several infectious diseases, including Whipple’s disease caused by the actinomycete \textit{Tropheryma whippelii}, and it can be added to the continuation phase of \textit{M. abscessus} therapy.\textsuperscript{1} Doxycycline was not identified as a hit against \textit{M. avium} by Low and colleagues.\textsuperscript{21} This highlights the importance of designing treatment regimens at the species level for rare infections when it is possible. Repurposing an already licensed, well tolerated, readily available antimicrobial drug with excellent tissue distribution properties such as doxycycline might be advantageous for \textit{M. chimaera}, as drug tissue penetration is important and drug discovery funding is not a priority.

MICs were established in this study using the CLSI microbroth dilution method\textsuperscript{28} with modifications to the media, incorporating the commonly used mycobacterial media Middlebrook 7H9 (ADC) with 0·05% Tween 80 detergent in place of Mueller Hinton Broth (Middlebrook OADC supplement) media. The use of this media enhanced the reproducibility of the assays by reducing mycobacterial clumping; which also minimised
the impact of drug tolerance arising from bacterial clumping, and it enabled the comparison of drug susceptibility between the three mycobacteria. However, it should be noted that such changes to the media can influence mycobacterial physiology through alternative carbon sources and cell wall composition, and these changes could alter antimicrobial drug efficacy. Better whole cell screening models are needed that are more representative of real-world events, which reproduce the in-vivo environments where the antimicrobial drugs act. This study focused on three mycobacterial reference strains: *M. chimaera* NCTC13781, *M. abscessus* ATCC19977, and *M. tuberculosis* H37Rv. Further exploration of drug repurposing options on a range of clinical isolates will be essential due to the wide distribution of antimicrobial drug MICs found across non-tuberculous mycobacteria.

This study is limited because it only demonstrates in-vitro drug efficiencies against an *M. chimaera* reference strain; and antimicrobial drug susceptibility testing in vitro does not always correlate with in-vivo activity. Griffith and Winthrop recently discussed the challenges of treating non-tuberculous mycobacteria: low MIC values might not correlate to clinical efficacy, clinical isolates might exhibit a broad range of MICs with no clear demarcation between susceptible and resistant isolates, and isolates might have high MIC values but no readily identifiable resistance mechanism.21 Despite these caveats, in-vitro susceptibility testing still has merit in research and clinical diagnostic settings.22 This is especially true for non-tuberculous mycobacterium, in which in-vitro drug efficacy data is incomplete and the scope for clinical trials to optimise treatments is restricted.27

This is an exploratory study; therefore, further work confirming antimicrobial drug activity against *M. chimaera* clinical isolates, the demonstration of in-vivo efficacy, and clinical validation of the observations in this study is required before these findings influence clinical practice. However, we identify the dianimoquinazoline, MMV675968, as an antimicrobial compound with 2 μM activity against *M. chimaera*, highlighting folate metabolism as a druggable pathway in this bacterium. In addition, we suggest drug repurposing opportunities for doxycycline, bedaquiline, and oxazolidinones in the treatment of rare but often fatal *M. chimaera* disease.

**Contributors**

DC, ES, SS, and SJW conceived and designed the study. DC, AG, ST, and ES conducted the experiments. All authors analysed and interpreted the data. DC and SJW drafted the manuscript. All authors reviewed and revised the manuscript. DC and SJW verified the underlying data. All authors gave final approval of the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Declaration of interests**

We declare no competing interests.

**Data sharing**

The Pathogen Box screening results for all the compounds are detailed in the appendix, and they are deposited in the ChEMBL database (https://www.ebi.ac.uk/chembl/) (ChEMBL ID: CHEMBL4665540).

**Acknowledgments**

The authors would like to thank Kirandeep Samby, Medicines for Malaria Venture (MMV), for supplying the Pathogen Box and additional compounds for screening and minimum inhibitory concentration determination. We acknowledge MMV for support, design, and supply of the Pathogen Box. MMV had no role in the study design or publication of this manuscript and the content of this publication is the responsibility of the authors. We acknowledge funding from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/RR016609/1) and the University of Sussex Junior Research Associate Scheme. This research was funded in whole, or in part, by the Wellcome Trust Institutional Strategic Support Fund (204833/Z/16/A). For the purpose of Open Access, the corresponding author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

**References**


Articles


25 Griffith DE, Winthrop KL. You gotta make me see, what does it mean to have an MIC? Chest 2021; 159: 462–64.
